Every story in this section, newest first — page 344 of 373.
Zai Lab Limited (NASDAQ:ZLAB) announced on January 6, 2026, that China’s National Medical Products Administration (NMPA) has approved the supplemental New Drug Application (sNDA) for AUGTYRO™ (repotrectinib).
This approval targets adult patients with advanced or metastatic solid tumors harboring a neurotrophic tyrosine receptor kinase (NTRK) gene fusion.
In a significant victory for food transparency advocates, a federal appeals court ruled on January 6, 2026, in favor of Natural Grocers (NASDAQ:NGVC), the Center for Food Safety, and a coalition of plaintiffs.
Abpro Holdings (NASDAQ:ABP) and South Korean biopharma giant Celltrion announced on January 6, 2026, that the U.S. FDA has cleared the Investigational New Drug (IND) application for ABP-102 (CT-P72).
This clearance transitions Abpro’s lead oncology program into the clinic, targeting a wide array of HER2-positive solid tumors, including breast, gastric, colorectal, and pancreatic cancers.
Alumis (NASDAQ:ALMS) surged as much as 82% in early trading Tuesday after its experimental oral drug, envudeucitinib, outperformed both a placebo and Amgen’s blockbuster Otezla in two Phase 3 trials for moderate-to-severe plaque psoriasis.
Genprex (NASDAQ:GNPX) announced landmark preliminary preclinical data on January 6, 2026, for its diabetes gene therapy candidate, GPX-002.
Cognition Therapeutics (NASDAQ:CGTX) announced on January 6, 2026, the publication of peer-reviewed results from its Phase 2 SHIMMER study in the journal Alzheimer's & Dementia.
Amgen (NASDAQ:AMGN) announced on January 6, 2026, the acquisition of Dark Blue Therapeutics, a UK-based biotech, for a total consideration of up to $840 million.
The deal centers on a first-in-class Targeted Protein Degrader (TPD) designed to treat specific, high-risk sub-populations of Acute Myeloid Leukemia (AML) and Acute Lymphoblastic Leukemia (ALL).
Actuate Therapeutics (NASDAQ:ACTU) reported successful Phase 1 results from its Actuate-1902 study on January 6, 2026.
The trial evaluated elraglusib, a first-in-class small molecule GSK-3β inhibitor, in 40 pediatric patients (ages 3–21) with relapsed or refractory solid tumors.
Edible Garden AG Incorporated (NASDAQ:EDBL) reported a 26.4% year-over-year increase in preliminary sales for the 2025 holiday period on January 6, 2026.
The gains were driven by robust demand for its core "Controlled Environment Agriculture" (CEA) products and a rapidly expanding retail footprint that now exceeds 5,000 locations across the U.S., Caribbean, and South America.
Atossa Therapeutics (NASDAQ:ATOS) reached a significant regulatory milestone on January 6, 2026, receiving a "Study May Proceed" letter from the U.S. FDA for its Investigational New Drug (IND) application.
Stereotaxis (NYSE:STXS), a global leader in endovascular surgical robotics, announced on Tuesday, January 6, 2026, that it has received U.S. Food and Drug Administration (FDA) approval for its MAGiC™ Magnetic Interventional Ablation Catheter.
TransCode Therapeutics (NASDAQ:RNAZ) today announced positive preclinical data demonstrating that its lead candidate, TTX-MC138, successfully reaches orthotopic glioblastoma tumors following intravenous administration and achieves sustained target engagement against miR-10b.
Lockheed Martin (NYSE:LMT) announced a transformative seven-year framework agreement with the U.S. Department of War on January 6, 2026.
The deal is designed to more than triple the annual production capacity of the PAC-3® Missile Segment Enhancement (MSE) interceptor, surging from current levels of approximately 600 units to a target of 2,000 units per year.
The agreement is a flagship outcome of the Department of War’s new Acquisition Transformation Strategy.
By providing long-term "demand certainty," the framework incentivizes Lockheed Martin and its massive global supply chain to invest in expanded tooling, facilities, and workforce.
To manage the financial burden of such a rapid scale-up, the deal utilizes a "collaborative financing model" that aims for cash neutrality in the early stages, allowing Lockheed to fund the expansion without immediate pressure on its balance sheet.
This "surging" of the "Arsenal of Freedom" follows a record-breaking 2025, where Lockheed Martin delivered 620 PAC-3 MSEs—a 20% year-over-year increase.
The PAC-3 MSE is a "hit-to-kill" interceptor, meaning it uses pure kinetic energy rather than a blast-fragmentation warhead to neutralize threats, making it the premier defense against advanced ballistic missiles, cruise missiles, and emerging hypersonic threats.
Profound Medical Corp. (NASDAQ:PROF) on Tuesday announced that Johns Hopkins Hospital has performed its first commercial prostate cancer treatment using the company's TULSA-PRO system, marking a key adoption milestone for the MRI-guided, incision-free ablation technology.
Bright Minds Biosciences (NASDAQ:DRUG) shares are under the spotlight following the announcement of "positive and significant" topline results from its Phase 2 BREAKTHROUGH study.
Alkermes (NASDAQ:ALKS) announced on January 6, 2026, that the U.S. FDA has granted Breakthrough Therapy Designation to alixorexton (formerly ALKS 2680) for the treatment of narcolepsy type 1 (NT1).
Sunoco LP (NYSE:SUN) issued its 2026 financial guidance on Tuesday, January 6, 2026, projecting a robust leap in earnings following a year of massive consolidation.
The partnership expects full-year adjusted EBITDA to land between $3.1 billion and $3.3 billion, a range that reflects the full integration of the Parkland acquisition and the upcoming close of the TanQuid terminal deal in Europe.
Ryder System (NYSE:R) announced the successful acquisition of Truck Service Depot, an Atlanta-based mobile maintenance firm, on January 5, 2026.
The move is a strategic bolt-on for Torque by Ryder™, the company’s rapidly expanding retail mobile maintenance division, as it seeks to capture a larger share of the on-demand fleet service market in the Southeast.
McEwen Mining (NYSE:MUX) and Canadian Gold Corp. completed their statutory plan of arrangement effective January 5, 2026, officially consolidating the high-grade Tartan Gold Mine into McEwen’s portfolio.
The merger, finalized at 8:00 a.m. Vancouver time, marks a strategic expansion for McEwen as it targets a doubling of its total production by 2030.
Apogee Therapeutics (NASDAQ:APGE) shares are trending today after the company reported positive interim Phase 1b results for zumilokibart (APG777), its half-life extended anti-IL-13 antibody.
Aclarion (NASDAQ:ACON) reached a significant clinical milestone on Tuesday, January 6, 2026, announcing the first patient enrollments at two prestigious new sites: Northwestern Medicine and Scripps Health.
This expansion brings the total number of active enrollment sites to four, with seven leading U.S. spine centers having completed full regulatory and operational setup.
Radware (NASDAQ:RDWR) announced Tuesday, January 6, 2026, that it has doubled its global cloud security mitigation capacity, jumping from 15 Tbps to 30 Tbps.
The massive upgrade comes in response to a "seismic shift" in the threat landscape, headlined by an 85% surge in network DDoS attacks during the first half of 2025.
Lithium Argentina AG (NYSE:LAR) shares are in focus after the company announced standout preliminary 2025 results for its Cauchari-Olaroz operation.
The project, a joint venture with Ganfeng Lithium, achieved full-year production of 34,100 tonnes of lithium carbonate—reaching the upper limit of its 30,000–35,000 tonne guidance.
AngioDynamics (NASDAQ:ANGO) on Tuesday reported fiscal second-quarter results that highlighted continued momentum in its high-margin Med Tech portfolio, with overall net sales rising 8.8% year over year to $79.4 million for the period ended Nov. 30, 2025.
